Press release

86th Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors

Thursday, 8 May 2014, ↓ directly to download

Although such a step will not become obligatory until 2015, the Board of Directors of Galenica Ltd. already submitted a resolution to shareholders to now amend the Articles of Association in line with the Ordinance against excessive compensation in listed corporations ("VegüV"). The shareholders approved all the proposals put forward by the Board of Directors.

_The 86th Annual General Meeting of Galenica Ltd. in Bern was attended by 399 shareholders representing a total of 73.2% of the registered voting shares of Galenica Ltd.

_The shareholders voted in favour of the proposals put forward by the Board of Directors on all items on the agenda. The Annual General Meeting approved the Annual Report and the 2013 Annual Financial Statements of Galenica Ltd. as well as the Consolidated Financial Statements of the Galenica Group for 2013 and discharged the members of the Board of Directors and the Corporate Executive Committee from liability for their activities in 2013. The Annual General Meeting also approved the proposal to renew the authorised share capital for another two years.
The Remuneration Report, submitted to shareholders for a consultative vote for the seventh time, was approved by more than 90%.
Also approved was the dividend of CHF 14.00 (+27.3%, prior year: CHF 11.00) proposed by the Board of Directors, which will be paid to shareholders on 16 May 2014.

Continue

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Contact

Dr. Jörg Kneubühler

Dr. Jörg Kneubühler

CEO Galenica Santé


Galenica Ltd.

Corporate Executive Committee
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Send link

Send as link



Links